.png "tel(1).png")
+86-591-87519654
South Pharmaceutical is a leading producer of paclitaxel and its intermediates in the Chinese pharmaceutical industry. It is the developer of the national standard "Technical Regulations for the Cultivation of Taxus mairei and Paclitaxel Raw Material Forests in the South," and one of the largest planting bases for Taxus mairei and production bases for paclitaxel and its intermediates in China. The company emphasizes technological innovation and the construction of its research and development team, holding 8 PCT international invention patents and 23 Chinese invention patents.
South Pharmaceutical has a strong sense of social responsibility, focusing on environmental protection and green development. It has a comprehensive environmental management and occupational health and safety management system (EHS system).
福建南方制药股份有限公司
FUJIAN SOUTH PHARMACEUTICAL CO., LTD.
福建南方制药股份有限公司（证券代码：831207）成立于2001年9月，致力于以紫杉醇原料药为代表的抗肿瘤药物的研发和生产，是一家集药物种植、研发、生产、销售于一体的GMP制药企业。公司旗下雪峰、瀚仙两个厂区占地面积共13.1万平方米，拥有4000亩优选南方红豆杉种植基地。
南方制药是中国制药行业领先的紫杉烷类原料药及中间体产品生产企业，是国家标准《南方红豆杉紫杉醇原料林丰产栽培技术规程》的制定者，是中国最大的红豆杉种植基地和紫杉烷类产品生产供应基地之一。公司重视技术革新和研发队伍的建设，现有8项PCT国际发明专利、23项中国发明专利。
南方制药富有良好的社会责任感，致力于环境保护和绿色发展，拥有完备的环境管理和职业健康安全管理体系（EHS体系）。
Fujian South Pharmaceutical Co., Ltd. (Stock Code: 831207) was established in September 2001. It is committed to the research and production of anti-tumor drugs, with paclitaxel as its representative, and is a GMP pharmaceutical enterprise integrating drug planting, research, production, and sales. The company's two factory areas, Xuefeng and Hanxian, cover a total area of 131,000 square meters and have a 4,000-acre high-quality southern yew planting base.
企业发展历程
Enterprise Development History- 2007年
通过国家药品GMP认证
Obtained National Drug GMP Certification
- 2008年
首次通过国家高技术企业资格认证
First-time accreditation as a National High-Tech Enterprise
- 2014年
旗下南方制药公司新三板上市（证券代码：831207）
South Pharmaceutical Company, a subsidiary, listed on the New Third Board (Securities Code: 831207)
- 2016年
通过美国FDA现场审计
Passed on-site audit by the U.S. Food and Drug Administration (FDA)
- 2017年
荣获高新技术企业、国家林业重点龙头企业等称号
Honored with titles such as High-Tech Enterprise and National Forestry Key Leading Enterprise
- 2018年
通过欧盟EDQM药品质量认证
Passed the European Directorate for the Quality of Medicines & HealthCare (EDQM) certification for drug quality
- 2021年
荣获国家专精特新“小巨人”企业称号
2021: Awarded the title of "National Specialized and Innovative 'Small Giant' Enterprise"
- 2022年
与上海熙华药业合作，投资「福建熙华医药产业园」
Cooperated with Shanghai Xihua Pharmaceutical Industry to invest in the 「Fujian Xihua Pharmaceutical Industrial Park」
